MAPLE GROVE, Minn. (Nov. 9, 2021) – HLT Inc., a Bracco Group Company, leading the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, has named Dr. Satya Shreenivas as its new chief medical officer. Dr. Shreenivas was most recently one of the primary structural heart physicians at The Christ Hospital and prior to that served as the director of structural heart program and section head of the catheterization lab at the University of Cincinnati. An experienced interventional cardiologist in structural heart procedures, Dr. Shreenivas has performed nearly 1,000 TAVR cases and participated in most of the pivotal trials for currently approved structural heart therapies.
“We have made remarkable progress with the HLT Meridian® TAVR Valve System,” said David R. Elizondo, president and CEO of HLT. “As we enter our clinical stages to help patients suffering from aortic disease with an effective, minimally invasive treatment, it is the right time for HLT to bring on an experienced and respected medical and industry professional to help guide us into the future. I am excited to have Dr. Shreenivas as part of our team.”
Angie Swenson, vice president of clinical affairs at HLT said, “In his role, we look forward to his medical expertise and strategic guidance on evidence development, clinical communications and publications, and training and support needs. Additionally, his oversight to ensure patient safety throughout product development processes, risk management, clinical trials, and safety surveillance will be valuable to our future success.”
Prior to accepting this position, Dr. Shreenivas has guided several companies that were performing early-stage medical device clinical trials. He also recently received his MBA from The Wharton School at the University of Pennsylvania. On joining HLT, Dr. Shreenivas said, “I am looking forward to working together with the HLT team to bring a
revolutionary aortic valve to market that will make the TAVR procedure safer and provide better long-term durability. My excitement at working with HLT is driven by this dual goal: A safer procedure and a longer lasting heart valve.”
HLT is committed to advancing TAVR therapies to improve lives. This will occur through innovation, technologies, and procedural techniques designed to achieve better, more predictable patient outcomes and improve the quality of life for TAVR patients.
With global headquarters in Maple Grove, Minn., HLT employs highly experienced healthcare and device industry professionals working in a creative, collaborative, and entrepreneurial environment.
As part of the Bracco Group, HLT benefits from the resources of a multinational conglomerate with broad expertise in cath lab technology and a dedication to continuous advancement. Bracco invests a significant amount of its resources in research and innovation across its portfolio of companies to improve patient outcomes and optimize treatment procedures.
To learn more about HLT, visit www.hltmedical.com.
Bracco is headquartered in Milan, Italy, and was founded in 1927. It is active in the healthcare sector through Bracco Imaging (diagnostic imaging), ACIST Medical Systems and HLT (cardiology) and the Centro Diagnostico Italiano diagnostic clinic. It has around 3,600 employees and annual total consolidated revenues of around 1.5 billion Euro. Bracco operates in more than 100 countries worldwide. To learn more about Bracco Group, visit www.bracco.com.
The HLT Meridian TAVR Valve System is an investigational device not available for sale in any geography.